Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

20
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
20
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

471
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
471
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

167
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
167
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

475
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
475
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

633
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NfL makes regulatory debut as neurodegenerative disease biomarker.

Nature reviews. Drug discovery·2023
Same author

NCATS's plan to grow the rare disease pipeline.

Nature reviews. Drug discovery·2023
Same author

GSK buys purine receptor antagonist for $2 billion.

Nature reviews. Drug discovery·2023
Same author

FDA approves second microbiome-based C. difficile therapy.

Nature reviews. Drug discovery·2023
Same author

Astellas buys complement inhibitor for $5.9 billion.

Nature reviews. Drug discovery·2023
Same author

Setting GPCRs free.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Feb 15, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

2017 FDA drug approvals.

Asher Mullard

    Nature Reviews. Drug Discovery
    |February 2, 2018
    PubMed
    Summary

    This article corrects a previously published Digital Object Identifier (DOI) to ensure accurate citation and retrieval of scientific literature. Ensuring correct DOIs is crucial for maintaining the integrity of research records and facilitating access to published studies.

    Area of Science:

    • Bibliometrics
    • Scholarly Communication

    Background:

    • Accurate citation is fundamental to scientific integrity.
    • Digital Object Identifiers (DOIs) are essential for locating research articles.
    • Errors in DOIs can impede access to scientific literature.

    Purpose of the Study:

    • To correct an erroneous Digital Object Identifier (DOI) for a specific publication.
    • To ensure the accurate referencing and retrieval of the scientific article associated with the corrected DOI.

    Main Methods:

    • Identification of the incorrect DOI.
    • Verification of the correct DOI through publisher records.
    • Issuance of a correction notice to the scientific community.

    Main Results:

    More Related Videos

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
    05:05

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

    Published on: November 4, 2011

    21.7K
    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
    10:03

    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

    Published on: August 1, 2013

    17.6K

    Related Experiment Videos

    Last Updated: Feb 15, 2026

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
    10:29

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

    Published on: November 12, 2010

    40.6K
    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
    05:05

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

    Published on: November 4, 2011

    21.7K
    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
    10:03

    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

    Published on: August 1, 2013

    17.6K
    • The incorrect DOI has been identified and rectified.
    • The corrected DOI is now available for accurate citation.
    • This ensures proper linkage to the intended research article.

    Conclusions:

    • The correction of this DOI enhances the reliability of scholarly databases.
    • Accurate DOIs are vital for the seamless flow of scientific information.
    • This ensures researchers can reliably access and cite relevant studies.